234 related articles for article (PubMed ID: 38124114)
21. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.
de Cubas AA; Korpershoek E; Inglada-Pérez L; Letouzé E; Currás-Freixes M; Fernández AF; Comino-Méndez I; Schiavi F; Mancikova V; Eisenhofer G; Mannelli M; Opocher G; Timmers H; Beuschlein F; de Krijger R; Cascon A; Rodríguez-Antona C; Fraga MF; Favier J; Gimenez-Roqueplo AP; Robledo M
Clin Cancer Res; 2015 Jul; 21(13):3020-30. PubMed ID: 25825477
[TBL] [Abstract][Full Text] [Related]
22. The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas.
Tufton N; Hearnden RJ; Berney DM; Drake WM; Parvanta L; Chapple JP; Akker SA
Endocr Relat Cancer; 2022 Nov; 29(11):589-598. PubMed ID: 35975974
[TBL] [Abstract][Full Text] [Related]
23. Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
Toledo RA; Qin Y; Cheng ZM; Gao Q; Iwata S; Silva GM; Prasad ML; Ocal IT; Rao S; Aronin N; Barontini M; Bruder J; Reddick RL; Chen Y; Aguiar RC; Dahia PL
Clin Cancer Res; 2016 May; 22(9):2301-10. PubMed ID: 26700204
[TBL] [Abstract][Full Text] [Related]
24. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
26. Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations.
Backman S; Maharjan R; Falk-Delgado A; Crona J; Cupisti K; Stålberg P; Hellman P; Björklund P
Sci Rep; 2017 Mar; 7():44943. PubMed ID: 28327598
[TBL] [Abstract][Full Text] [Related]
27. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
28. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
29. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
[TBL] [Abstract][Full Text] [Related]
30. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
31. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas.
O'Toole SM; Dénes J; Robledo M; Stratakis CA; Korbonits M
Endocr Relat Cancer; 2015 Aug; 22(4):T105-22. PubMed ID: 26113600
[TBL] [Abstract][Full Text] [Related]
32. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.
Hadrava Vanova K; Pang Y; Krobova L; Kraus M; Nahacka Z; Boukalova S; Pack SD; Zobalova R; Zhu J; Huynh TT; Jochmanova I; Uher O; Hubackova S; Dvorakova S; Garrett TJ; Ghayee HK; Wu X; Schuster B; Knapp PE; Frysak Z; Hartmann I; Nilubol N; Cerny J; Taieb D; Rohlena J; Neuzil J; Yang C; Pacak K
J Natl Cancer Inst; 2022 Jan; 114(1):130-138. PubMed ID: 34415331
[TBL] [Abstract][Full Text] [Related]
33. Pathology and genetics of phaeochromocytoma and paraganglioma.
Turchini J; Cheung VKY; Tischler AS; De Krijger RR; Gill AJ
Histopathology; 2018 Jan; 72(1):97-105. PubMed ID: 29239044
[TBL] [Abstract][Full Text] [Related]
34. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
35. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
36. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
37. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
Eisenhofer G; Pacak K; Huynh TT; Qin N; Bratslavsky G; Linehan WM; Mannelli M; Friberg P; Grebe SK; Timmers HJ; Bornstein SR; Lenders JW
Endocr Relat Cancer; 2011 Feb; 18(1):97-111. PubMed ID: 21051559
[TBL] [Abstract][Full Text] [Related]
38. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
39. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]